PARP1 Deficiency Reduces Amyloid Pathology in Familial AD Model
New preclinical work links PARP1 deficiency to reduced amyloid burden and cognitive preservation in a familial Alzheimer's model.
Early Breast Cancer at ASCO 2026: Trials to Watch
ASCO 2026 is expected to bring pivotal data on adjuvant and neoadjuvant strategies in early breast cancer. Here is what clinicians should watch for.
Lower-Dose Tirzepatide: Can It Sustain Weight Loss Long-Term?
New evidence examines whether reduced tirzepatide doses can maintain weight loss, with implications for long-term obesity management in primary care.
Hantavirus: Lethality, Transmission and What GPs Need to Know
Hantavirus carries case fatality rates up to 40% in some syndromes. Here is what clinicians and the public genuinely need to worry about.
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
The pipeline for pediatric oncology drugs remains sparse, with most candidates failing to progress beyond early-phase trials to approval.
Abdominal Obesity Linked to More Severe Menopause Symptoms
Women with central adiposity report more frequent and severe vasomotor and psychological menopause symptoms, with waist circumference emerging as a key clinical marker.
SGLT2 Inhibitors and Ferroptosis: A New Mechanistic Picture in HF
Emerging evidence links SGLT2 inhibitors' cardiac benefit to ferroptosis suppression, offering a potential mechanistic explanation for their efficacy in heart failure.
Dupilumab in Severe Asthma: Real-World Cohort Data Begin to Arrive
Three new studies examine dupilumab and biologic therapy in severe type 2 asthma, adding real-world weight to existing trial evidence.
SGLT2 Inhibitors and Ferroptosis: A New Mechanistic Picture in HF
Emerging evidence links SGLT2 inhibitors' cardiac benefit to ferroptosis suppression, offering a potential mechanistic explanation for their efficacy in heart failure.
2025 AHA/ACC Hypertension Guidelines: What GPs Need Now
The 2025 AHA/ACC hypertension guidelines update prescribing priorities. Here is what the evidence says about antihypertensive management today.
PCSK9 Inhibitors Move Upstream: Evolocumab Tested in Diabetes Without Known Atherosclerosis
VESALIUS-CV tests evolocumab in diabetic patients without established atherosclerosis, while new trials probe plaque biology and lipid pathways beyond LDL.
SGLT2 Inhibitors Post-Heart Transplant: What the Data Show
3 min readAtrial Fibrillation and Cardio-Kidney-Metabolic Risk: A Systemic Challenge
2 min readAtrial Fibrillation Complexity: How Reliable is Registry Data?
3 min readTAVI and Aortic Dissection Risk: Is Valve Type a Factor?
3 min readSSEPs to Monitor Cerebral Perfusion During TCAR TAVR Procedures
2 min readLower-Dose Tirzepatide: Can It Sustain Weight Loss Long-Term?
New evidence examines whether reduced tirzepatide doses can maintain weight loss, with implications for long-term obesity management in primary care.
Oral Orforglipron Sustains Weight Loss After Injectable GLP-1 Therapy
The ATTAIN-MAINTAIN trial shows oral orforglipron preserves most injectable-achieved weight loss at 52 weeks, offering a scalable transition option.
GLP-1 Drugs and Oral Medication Absorption: What Prescribers Need to Know
GLP-1 receptor agonists slow gastric emptying, raising theoretical concerns about altered absorption of time-sensitive oral drugs. Evidence remains thin.
What Still Eludes Us in MASH Research?
3 min readLorlatinib and New-Onset Diabetes Practical Monitoring for Oncologists
3 min readLorlatinib and the Enigma of Autoantibody-Negative Diabetes
3 min readUnraveling MASH: Implications for Clinical Practice
2 min readSGLT2 Inhibitors: Promise and Peril in Prader-Willi Syndrome?
4 min readOpportunistic Osteoporosis Screening from CT Scans A Validated Approach?
4 min readPARP1 Deficiency Reduces Amyloid Pathology in Familial AD Model
New preclinical work links PARP1 deficiency to reduced amyloid burden and cognitive preservation in a familial Alzheimer's model.
Brain Cooling After Thrombectomy: Does Hypothermia Aid LVO Recovery?
Targeted temperature management after mechanical thrombectomy for LVO stroke is under active investigation, but the evidence base remains preliminary.
Gut Microbiota Signal the Brain via the Vagus Nerve: What GPs Should Know
The gut-brain axis operates partly through vagal afferent neurons. Here is what the established mechanistic evidence means for everyday practice.